A study entitled “Recovery Potential in Patients who Died after Withdrawal of Life-sustaining Treatment” has recently been published in the Journal of Trauma (1). In the article, the authors analyzed the ability of certain clinical scales to predict the survival and functional recovery of patients with severe head trauma. The most remarkable conclusion of the study, which was conducted in 18 hospitals in the United States, was that “some patients with traumatic brain injuries who died after withdrawal of life support may have recovered”. In view of these findings, the authors’ main recommendation was to propose a more cautious approach when making early decisions about withdrawing life-sustaining treatments in patients with these injuries.

The publication of the aforementioned study has generated justifiable concern and many questions have been raised. Are the data from this study and the conclusions drawn from them reliable? Were these decisions to withdraw life-sustaining treatment made hastily? What were the reasons that led to the apparently hasty decision to withdraw treatment? Can the data from this study be extrapolated to other geographical areas other than those of medical centers in the United States?

While agreeing with the fact that there is a high level of prognostic uncertainty in some patients with severe head trauma, it is important to note that the methodology used in the study is probably not appropriate to reach the conclusions drawn therein.

At present, there are two situations in patients with severe head trauma in which there is a scientific and ethical consensus regarding the decision to limit the therapeutic intensity. One is “whole brain death”, in which all the activity of the intracranial central nervous system has ceased, and which is equivalent to death of the person; the other is the “persistent vegetative state”, a situation frequently derived from brain damage caused by prolonged cardiac arrest, and whose diagnosis can only be established at least 6 months after the event.

Excluding these two diagnoses, there is a wide spectrum of clinical outcomes in patients with severe head trauma, ranging from patients with ad integrum neurological recovery to those with severe neurological disability, the most paradigmatic of which is the “minimally conscious state”.

Withholding or complete withdrawal of therapeutic or diagnostic actions (life-sustaining treatment) in patients with severe head injury must always begin with an analysis of the utility or futility (probabilistic or qualitative) of the possible actions. Clinical decisions must always be made by experts, with analysis not only of the utility/futility of the clinical action, but also of the impact that the treatment will have on the clinical process and the patient’s life.

Once the clinical context, the therapeutic approach and the likelihood of its utility have been considered, the patient’s representatives should be informed, given that patients with severe head trauma are generally not competent to make decisions. These representatives, usually members of the family unit, aware of the patient’s own values, must act in accordance with these, and must never propose actions that are contrary to medical lex artis ad hoc (i.e., the doctor is required to have complied with what is required on each occasion, following what medical science determines at that moment, but also taking into consideration the patient’s situation).

The study mentioned at the beginning of this article does not refer to specific cases, but is a multicenter study, and employs tools (such as the GOSE scale or the DRS scale) that can be considered useful for the evaluation of global clinical outcomes, but that should not be used for the analysis of clinical outcomes in specific patients.

Another limitation of the study is that it lacks a clear definition of the actions referred to as “withdrawal of support/comfort measures”, which, as we know, are not standardized, nor are they homogeneous in different hospitals.

Moreover, withholding therapeutic measures should not be associated with a dichotomous action. Instead, treatment limitation, where indicated, should refer to those futile measures, but not necessarily extend to all therapeutic actions.

In their study, the authors did not analyze the associated socioeconomic aspects, which means that the study results cannot be extrapolated to care models other than the United States. Consequently, their healthcare model is based, in many cases, on insurance companies, which do not provide universal coverage of medical care sine die, in contrast to other countries, such as Spain, where there are no predefined restrictions on the duration of treatment in intensive care units or rehabilitation services.

In addition to the aforementioned factors, there are others that cause the study to have elements of bias that mean it cannot be extrapolated to other healthcare settings. Thus, the study reports that the patient’s representatives are “asked” whether or not to continue the therapy. This violates ethical and humanistic principles, since the treatment approach must always be made by the healthcare providers, although the patient or their representative should be informed. This information on the treatment approach (which includes the best clinical interest of the patient) must be assessed by the family and aligned with the values previously expressed by the patient. As also mentioned above, a second element of study bias — and which could favor the withdrawal of life support measures — was the fact that each day of hospital stay that was not covered by medical insurance, or that could not be paid directly by the patient’s relatives, could influence the decisions of families to be “favorable” towards the withdrawal of therapeutic measures.

Good ethical practice, based on consensus clinical decisions by experts, an evaluation of therapeutic futility/utility with information for the family (which must make its decision based on the patient’s values) and free universal healthcare coverage, such as the one we currently have in Spain, could possibly give different results to those mentioned above, and not have sounded an unnecessary alarm.

Jose María Domínguez

Bioethics Observatory – Institute of Life Sciences

Catholic University of Valencia

 

References:

(1) Sanders WR, Barber JK, Temkin NR, Foreman B, Giacino JT, Williamson T, Edlow BL, Manley GT, Bodien YG. Recovery Potential in Patients Who Died After Withdrawal of Life-Sustaining Treatment: A TRACK-TBI Propensity Score Analysis. J Neurotrauma. 2024 May 13. doi: 10.1089/neu.2024.0014. Epub ahead of print. PMID: 38739032.

Share This Story, Choose Your Platform!